© 2023 MJH Life Sciences and CGTLive™. All rights reserved.
© 2023 MJH Life Sciences™ and CGTLive™. All rights reserved.
April 25, 2022
In 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.
December 03, 2021
The cell therapy is approved for B-cell non-Hodgkin lymphoma and B-ALL in China.
December 02, 2021
Two sites in California and Missouri are actively recruiting patients with r/r LBCL who were treated with tisagenlecleucel to receive efineptakin alfa in the study.
November 24, 2021
In 26 patients with LBCL followed for at least 28 days, the objective response rate (ORR) was 58% with complete responses (CRs) in 38% of patients.
October 31, 2021
Doctors debated the roles of allogeneic hematopoietic stem cell transplant and CAR T-cell therapy for the treatment of aggressive B-cell lymphoma.
October 25, 2021
Michael Wang, MD, discussed the evolution of treatment in the MCL space specifically with the emergence of chimeric antigen receptor T cells.
September 19, 2021
The new technologies were made available as a result of the licensing agreement between MD Anderson and Bellicum Pharmaceuticals.
March 26, 2020
Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.
August 08, 2019
Kieron Dunleavy, MD, discusses the current treatment paradigm in mantle call lymphoma and the emerging potential for CAR T-cell therapy.